News ArticleGlenmark Pharmaceuticals Posts Q2 FY2027 Consolidated Profit of ₹7,148.40 Million Amid Exceptional Charges
Company reports total revenue from operations of ₹42,473.28 million for quarter ended September 30, 2026, with profit adjusted for ₹2,838.75 million exceptional items.
Glenmark Pharmaceuticals Limited announced its unaudited consolidated financial results for the quarter ended September 30, 2026. The company reported a profit after tax of ₹7,148.40 million despite exceptional items amounting to ₹2,838.75 million. Total consolidated revenue from operations reached ₹42,473.28 million during the quarter with comprehensive income of ₹2,314.05 million attributed to owners.
Glenmark Pharmaceuticals Limited
Financial Results
Glenmark Pharmaceuticals Limited reported its unaudited consolidated financial results for the quarter ended September 30, 2026, posting a profit after tax of ₹7,148.40 million. The results include an exceptional expense of ₹2,838.75 million that affected the profitability during the period.
For the quarter ended September 30, 2026, Glenmark posted total consolidated revenue from operations of ₹42,473.28 million, comprising net sales of ₹41,570.91 million and other operating income of ₹902.37 million.
Total consolidated income including other income stood at ₹42,498.69 million. Expenses for the quarter were ₹36,277.06 million, encompassing costs such as materials consumed, employee benefits, and depreciation.
Profit before exceptional items and tax was ₹6,221.63 million, but after accounting for exceptional items of ₹2,838.75 million, profit before tax decreased to ₹3,382.88 million.
Tax expense for the period included a current tax charge of ₹1,279.93 million and a deferred tax credit of ₹535.35 million. The company’s profit after tax attributable to owners was ₹2,637.83 million.
Other comprehensive income for the quarter was a loss of ₹323.82 million, leading to total comprehensive income of ₹2,314.05 million attributable to shareholders.
Highlights
- Consolidated revenue from operations: ₹42,473.28 million for Q2 FY2027
- Profit after tax (consolidated): ₹7,148.40 million for Q2 FY2027
- Exceptional items expense: ₹2,838.75 million impacting profitability
- Basic earnings per share (consolidated): ₹21.63 for Q2 FY2027
- Total comprehensive income attributable to owners: ₹2,314.05 million
Key Data Snapshot
What happened
- Glenmark Pharmaceuticals approved its unaudited consolidated financial results for the quarter ending September 30, 2026.
- The company reported a consolidated profit after tax of ₹7,148.40 million despite recognizing exceptional expenses.
- Total revenue from operations for the quarter was ₹42,473.28 million including net sales and other operating income.
Key details
- Profit before exceptional items and tax was ₹6,221.63 million for the quarter.
- Exceptional items amounting to ₹2,838.75 million reduced profit before tax to ₹3,382.88 million.
- Total expenses for the quarter were ₹36,277.06 million covering various operating and finance costs.
- Basic earnings per share on consolidated basis was ₹21.63 for the quarter.
- Other comprehensive income recorded a loss of ₹323.82 million for the same period.
Financial performance
- Consolidated net sales for the quarter ended September 30, 2026, were ₹41,570.91 million.
- Other operating income contributed ₹902.37 million to total revenue.
- The company's total comprehensive income attributable to owners was ₹2,314.05 million during the quarter.
Regulatory and governance context
- Results were approved by the Board of Directors at the meeting held on November 5, 2026.
- The financials comprise an unaudited report subjected to limited review.
- Disclosure complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Consolidated revenue from operations: ₹42,473.28 million for Q2 FY2027
- Profit after tax (consolidated): ₹7,148.40 million for Q2 FY2027
- Exceptional items expense: ₹2,838.75 million impacting profitability
- Basic earnings per share (consolidated): ₹21.63 for Q2 FY2027
- Total comprehensive income attributable to owners: ₹2,314.05 million
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Life Insurance Corporation of India Reports Q2 FY 2027 Results and Appoints Smt Naga Nalini Kalluri as Chief Compliance Officer
Life Insurance Corporation of India disclosed its unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2026. Additionally, the board appointed Smt Naga Nalini Kalluri as Chief Compliance Officer and Key Managerial Personnel, effective November 6, 2026, replacing the outgoing officer.
Read Full Story
Sansera Engineering Posts Rs 1,092.53 Million Profit in Q2 2026 After US$2 Million Lawsuit Settlement
Sansera Engineering Limited announced unaudited standalone results for Q2 and half year ended September 30, 2026, registering a net profit of Rs 1,092.53 million for the quarter and Rs 1,959.30 million for six months. The company settled a United States civil lawsuit by paying US$2 million during this period, recognized as an exceptional expense.
Read Full Story
Godfrey Phillips India Announces Q2 FY2027 Financial Results and Rs. 10 Per Share Interim Dividend
Godfrey Phillips India Limited approved its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company declared an interim dividend of 500% or Rs. 10 per equity share of Rs. 2 each for the fiscal year ending March 31, 2027.
Read Full Story
